Nov 12, 2024 4:30pm EST Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Sep 16, 2024 7:30am EDT Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024